Novel advances in pancreatic cancer treatment

  title={Novel advances in pancreatic cancer treatment},
  author={Michel Vulfovich and Caio Max S Rocha-Lima},
  journal={Expert Review of Anticancer Therapy},
  pages={1002 - 993}
Little progress has been made on the treatment of advanced pancreatic cancer. Gemcitabine has been an acceptable standard for more than a decade. The benefit of single-agent gemcitabine in advanced and metastatic pancreatic cancer is small. Adding other chemotherapy agents to gemcitabine has not resulted in meaningful improvement in survival. The randomized trials studying the addition of molecular targeting agents (cetuximab, bevacizumab, farnesyl transferase inhibitors and metalloproteinase… 

Cucurbitacin B, a novel in vivo potentiator of gemcitabine with low toxicity in the treatment of pancreatic cancer

It is shown that the triterpenoid cucurbitacin B inhibited tumour growth in pancreatic cancer cells by inhibition of the JAK/STAT pathway, and synergistically increased antiproliferative effects of gemcitabine in vitro.

Advances in early diagnosis and therapy of pancreatic cancer.

Molecular targets and biological modifiers in gastric cancer.

The involvement of E-cadherin, EGFR, ERBB2, MMR genes, KRAS, and PIK3CA in the development and progression of gastric cancer and their role as biomarkers or as novel putative targets for therapy are discussed.

Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer

These findings demonstrate the effectiveness of synthetic lethal RNAi screening as a tool for identifying sensitizing targets to chemotherapeutic agents and indicate that CHK1 could serve as a putative therapeutic target for sensitizing pancreatic cancer cells to gemcitabine.

RESEARCH PAPER Cucurbitacin B, a novel in vivo potentiator of gemcitabine with low toxicity in the treatment of pancreatic cancer

Combination of cucurbitacin B and gemcitabine had profound anti-proliferative effects in vivo against xenografts of human pancreatic cancer cells, without any significant signs of toxicity.

Preliminary study of cytotoxic effects of photodynamic therapy and immunotherapy on human pancreatic cancer cells

Examination of cytotoxic effects of antibody C225 (an anti-HER-1/EGFR monoclonal antibody) and Photofrin-mediated PDT on two human pancreatic cancer cell lines indicated that these treatments could block various proliferation pathways of pancreatic cancers cells through different mechanisms.

Multidisciplinary management of resectable adenocarcinoma of the pancreatic head

The rationale for the use of and the outcomes that may be achieved through theUse of a multidisciplinary approach to patients with resectable adenocarcinoma of the pancreatic head are reviewed.

Critical role of miRNAs in pancreatic cancer.

The present review focuses on recent advances regarding the roles of miRNAs in PC and their practical value.

Anticancer effects of an oncolytic parvovirus combined with non-conventional therapeutics on pancreatic carcinoma cell lines.

In this study, the effect of infection with oncolytic H-1 parvovirus combined with antibiotic norfloxacin (NFX) or phytoalexin resveratrol on the survival of cell lines Panc-1 and BxPC3 derived from human pancreatic carcinoma was tested.



Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.

  • M. MooreD. Goldstein W. Parulekar
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2007
To the authors' knowledge, this randomized phase III trial is the first to demonstrate statistically significantly improved survival in advanced pancreatic cancer by adding any agent to gemcitabine.

Gemcitabine plus celecoxib (GECO) in advanced pancreatic cancer: a phase II trial

GEM in combination with celecoxib showed low toxicity, good clinical benefit rate and good disease control, and further clinical investigation is warranted.

Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer.

  • H. KindlerG. Friberg E. Vokes
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2005
The combination of bevacizumab plus gemcitabine is active in advanced pancreatic cancer patients, and the response rate and overall survival of patients who received gem citabine with the recombinant humanized anti-VEGF monoclonal antibody was assessed.

A Phase II study of gemcitabine plus zoledronic acid in subjects with Stage IV pancreatic cancer.

  • J. CoxT. Cartwright L. Asmar
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2006
Zoledronic acid in combination with gemcitabine was well-tolerated in this study and future genomic testing is proposed for responders.

Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer.

There was a significant survival benefit for chemotherapy over best supportive care and gem citabine combinations over gemcitabine alone, which supports the use of gemcitABine-based combination chemotherapy in the treatment of advanced pancreatic cancer.

A randomized phase II study of axitinib (AG-013736) and gemcitabine versus gemcitabine in advanced pancreatic cancer, preceded by a phase I component

Current standard of care for patients with advanced pancreatic cancer is gemcitabine- based chemotherapy, but axitinib (AG) is a potent inhibitor of vascular endo...

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

It is demonstrated that gemcitabine is more effective than 5-FU in alleviation of some disease-related symptoms in patients with advanced, symptomatic pancreas cancer and confers a modest survival advantage over treatment with5-FU.

Epidermal Growth Factor Receptor-Targeted Therapy for Pancreatic Cancer

Agents capable of inhibiting EGFR activity with resultant inhibition of cell proliferation and angiogenesis have significant potential as chemotherapeutic agents for the treatment of pancreatic adenocarcinomas as well as multiple other malignancies.

Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial.

Cetuximab in combination with gemcitabine showed promising activity against advanced pancreatic cancer.

A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma.

In advanced pancreatic carcinomas with a poor prognosis, FUP was superior to FU in terms of response and progression-free survival, but not in termsof overall survival.